<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="cytoa24511" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cytometry A</journal-id><journal-id journal-id-type="iso-abbrev">Cytometry A</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">CYTO</journal-id><journal-title-group><journal-title>Cytometry</journal-title></journal-title-group><issn pub-type="ppub">1552-4922</issn><issn pub-type="epub">1552-4930</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9298126</article-id><article-id pub-id-type="pmcid-ver">PMC9298126.1</article-id><article-id pub-id-type="pmcaid">9298126</article-id><article-id pub-id-type="pmcaiid">9298126</article-id><article-id pub-id-type="pmid">34719867</article-id><article-id pub-id-type="doi">10.1002/cyto.a.24511</article-id><article-id pub-id-type="publisher-id">CYTOA24511</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Omip</subject></subj-group><subj-group subj-group-type="heading"><subject>Omip</subject></subj-group></article-categories><title-group><article-title>OMIP &#8208; 081: A new 21&#8208;monoclonal antibody 10&#8208;color panel for diagnostic polychromatic immunophenotyping</article-title><alt-title alt-title-type="left-running-head">Huys et al.</alt-title></title-group><contrib-group><contrib id="cytoa24511-cr-0001" contrib-type="author"><name name-style="western"><surname>Huys</surname><given-names initials="EHLPG">Erik H. L. P. G.</given-names></name><xref rid="cytoa24511-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cytoa24511-cr-0002" contrib-type="author"><name name-style="western"><surname>Hobo</surname><given-names initials="W">Willemijn</given-names></name><xref rid="cytoa24511-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cytoa24511-cr-0003" contrib-type="author" corresp="yes"><name name-style="western"><surname>Preijers</surname><given-names initials="FWMB">Frank W. M. B.</given-names></name><xref rid="cytoa24511-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>frank.preijers@radboudumc.nl</email></address></contrib></contrib-group><aff id="cytoa24511-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Laboratory Medicine, Laboratory for Hematology</named-content>
<institution>Radboud University Medical Center</institution>
<city>Nijmegen</city>
<country country="NL">The Netherlands</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Frank W. M. B. Preijers, Department of Laboratory Medicine, Laboratory for Hematology, Radboud University Medical Center, Geert Grooteplein 8, Nijmegen, The Netherlands.<break/>
Email: <email>frank.preijers@radboudumc.nl</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>11</month><year>2021</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2022</year></pub-date><volume>101</volume><issue seq="90">2</issue><issue-id pub-id-type="pmc-issue-id">412791</issue-id><issue-id pub-id-type="doi">10.1002/cyto.a.v101.2</issue-id><fpage>117</fpage><lpage>121</lpage><history><date date-type="rev-recd"><day>05</day><month>10</month><year>2021</year></date><date date-type="received"><day>15</day><month>4</month><year>2021</year></date><date date-type="accepted"><day>18</day><month>10</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>07</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>21</day><month>07</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2022-07-29 10:19:40.070"><day>29</day><month>07</month><year>2022</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2021 The Authors. <italic toggle="yes">Cytometry Part A</italic> published by Wiley Periodicals LLC on behalf of International Society for Advancement of Cytometry.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CYTO-101-117.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CYTO-101-117.pdf"/><abstract><title>Abstract</title><p>The 10&#8208;color panel consisting of 21 monoclonal antibodies (mAbs) is developed as a one&#8208;tube panel to detect leukemia and lymphoma cells in all hematopoietic cell lineages. In particular, this tube is mentioned for a fast screening to identify aberrant cells in samples suspected for malignant cell localization and to enable comprehensive immunophenotyping of samples with low cell counts. The panel contains mAbs for selection of the populations and mAbs against target antigens on the various hematopoietic maturation stages. Due to the limited number of PMTs in most used flow cytometers for clinical purposes, stacking of conjugates in one color is needed to include all relevant markers for simultaneous analysis of the aberrant cells. The 21&#8208;mAb panel is tested on peripheral blood (PB), and bone marrow (BM) samples and enables an efficient and correct identification of hematological malignancies. This panel improves the diagnostic potential.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cytoa24511-kwd-0001">21&#8208;mAbs/10&#8208;color</kwd><kwd id="cytoa24511-kwd-0002">antibody stacking</kwd><kwd id="cytoa24511-kwd-0003">flow cytometry</kwd><kwd id="cytoa24511-kwd-0004">leukemia/lymphoma</kwd><kwd id="cytoa24511-kwd-0005">polychromatic immunophenotyping</kwd><kwd id="cytoa24511-kwd-0006">screening</kwd></kwd-group><counts><fig-count count="1"/><table-count count="3"/><page-count count="5"/><word-count count="2592"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2022</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.1.7 mode:remove_FC converted:20.07.2022</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="cytoa24511-cit-9001"><string-name name-style="western"><surname>Huys</surname><given-names>EHLPG</given-names></string-name>, <string-name name-style="western"><surname>Hobo</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Preijers</surname><given-names>FWMB</given-names></string-name>. <article-title>OMIP &#8208; 081: A new 21&#8208;monoclonal antibody 10&#8208;color panel for diagnostic polychromatic immunophenotyping</article-title>. <source>Cytometry</source>. <year>2022</year>;<volume>101</volume>:<fpage>117</fpage>&#8211;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1002/cyto.a.24511</pub-id><pub-id pub-id-type="pmid">34719867</pub-id><pub-id pub-id-type="pmcid">PMC9298126</pub-id></mixed-citation>
</p></notes></front><body id="cytoa24511-body-0001"><sec id="cytoa24511-sec-0001"><label>1</label><title>PURPOSE AND APPROPRIATE SAMPLE TYPES</title><p>The 10&#8208;color panel consisting of 21 monoclonal antibodies (mAbs) is developed as a one&#8208;tube panel to detect leukemia and lymphoma cells in all hematopoietic cell lineages. In particular, this tube is mentioned for a fast screening to identify aberrant cells in samples suspected for malignant cell localization and to enable comprehensive immunophenotyping of samples with low cell counts. The panel contains mAbs for selection of the populations and mAbs against target antigens on the various hematopoietic maturation stages. Due to the limited number of PMTs in most used flow cytometers for clinical purposes, stacking of conjugates in one color is needed to include all relevant markers for simultaneous analysis of the aberrant cells. The 21&#8208;mAb panel is tested on peripheral blood (PB), and bone marrow (BM) samples and enables an efficient and correct identification of hematological malignancies. This panel improves the diagnostic potential.</p></sec><sec sec-type="background" id="cytoa24511-sec-0002"><label>2</label><title>BACKGROUND</title><p>The rapid and sensitive multiparameter detection, even at a single cell level, renders flow cytometry (FCM) to a powerful tool to distinguish malignant hematopoietic cells from normal cells. Due to the technical aspects of the FCMs for diagnostics, currently immunophenotypic analyses often consist of up to 10&#8208;mAb panels and oblige the use of multiple tubes that contain the specific combinations of mAbs to characterize the aberrant cell population. However, this approach hampers the evaluation of co&#8208;expression patterns from mAbs that are present in different tubes. In particular, determinations like minimal residual disease (MRD) or characterization of very small cell populations need high&#8208;level multicolor analyses [<xref rid="cytoa24511-bib-0001" ref-type="bibr">1</xref>, <xref rid="cytoa24511-bib-0002" ref-type="bibr">2</xref>, <xref rid="cytoa24511-bib-0003" ref-type="bibr">3</xref>, <xref rid="cytoa24511-bib-0004" ref-type="bibr">4</xref>, <xref rid="cytoa24511-bib-0005" ref-type="bibr">5</xref>]. Furthermore, the multiple color analysis using multiple tubes is time consuming and cost ineffective. Therefore, a one&#8208;tube approach with 21 mAbs is more sensitive and adequate to detect aberrant cells. Besides the need of a subsequent second step and more targeted immunophenotyping will be reduced (Table&#160;<xref rid="cytoa24511-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="cytoa24511-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Summary table for application of the OMIP</p></caption><table frame="hsides" rules="cols"><col align="left" span="1"/><col align="left" span="1"/><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Purpose</td><td align="left" valign="top" rowspan="1" colspan="1">Improvement of immunophenotyping of leukemia and lymphoma by a fast one&#8208;tube screening panel consisting of 10 colors and 21 mAbs</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Species</td><td align="left" valign="top" rowspan="1" colspan="1">Human</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cell type</td><td align="left" valign="top" rowspan="1" colspan="1">Bone marrow, peripheral blood</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cross&#8208;references</td><td align="left" valign="top" rowspan="1" colspan="1">OMIP 10 (see Reference [<xref rid="cytoa24511-bib-0002" ref-type="bibr">2</xref>])</td></tr></tbody></table></table-wrap><p>At present, the application of panels with more than 10 colors is restricted technically for diagnostic purposes. In order of improve immunophenotyping by applying more than 10 mAbs in one tube, stacking of antibodies within one fluorescence channel is therefore needed. We developed a screening panel using stacking up to three antibodies resulting in up to 23 evaluable parameters (FS, SS, and mAbs). Similar approaches of stacking have been applied by other groups [<xref rid="cytoa24511-bib-0006" ref-type="bibr">6</xref>, <xref rid="cytoa24511-bib-0007" ref-type="bibr">7</xref>, <xref rid="cytoa24511-bib-0008" ref-type="bibr">8</xref>, <xref rid="cytoa24511-bib-0009" ref-type="bibr">9</xref>, <xref rid="cytoa24511-bib-0010" ref-type="bibr">10</xref>]. This 21&#8208;mAb in 10&#8208;colors panel can be a reliable alternative for the use of 23&#8208;PMT containing FCMs that are presently hardly available.</p><p>After selection of the target antigens and search for suitable mAb clones and fluorochromes (Table&#160;<xref rid="cytoa24511-tbl-0002" ref-type="table">2</xref>), all mAbs were titrated to find the optimal concentration. Subsequently, compensation of spectral overlap and extensive balancing of the panel was performed to establish suitable and correct combinations of stacked mAbs with preservation of their capacity to separate and identify the different hematopoietic cell populations and maturation stages.</p><table-wrap position="float" id="cytoa24511-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Reagents used for the OMIP</p></caption><table frame="hsides" rules="cols"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Specificity</th><th align="left" valign="bottom" rowspan="1" colspan="1">Clone</th><th align="left" valign="bottom" rowspan="1" colspan="1">Fluorochrome</th><th align="left" valign="bottom" rowspan="1" colspan="1">Purpose</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">CD45</td><td align="left" valign="top" rowspan="1" colspan="1">J33</td><td align="left" valign="top" rowspan="1" colspan="1">KO</td><td align="left" valign="top" rowspan="1" colspan="1">WBC subpopulations</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD3</td><td align="left" valign="top" rowspan="1" colspan="1">UCHT1</td><td align="left" valign="top" rowspan="1" colspan="1">APC&#8208;AF750</td><td align="left" valign="top" rowspan="1" colspan="1">Mature T cells</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD4</td><td align="left" valign="top" rowspan="1" colspan="1">SFCI12T4B11</td><td align="left" valign="top" rowspan="1" colspan="1">PE&#8208;Cy7</td><td align="left" valign="top" rowspan="1" colspan="1">Helper T cells, Monocyte lineage</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD8</td><td align="left" valign="top" rowspan="1" colspan="1">B9.11</td><td align="left" valign="top" rowspan="1" colspan="1">PacB</td><td align="left" valign="top" rowspan="1" colspan="1">Cytotoxic T cells, NK&#8208;cell subset</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD2</td><td align="left" valign="top" rowspan="1" colspan="1">39C15</td><td align="left" valign="top" rowspan="1" colspan="1">APC&#8208;AF700</td><td align="left" valign="top" rowspan="1" colspan="1">T&#8208;cell lineage, NK&#8208;cell subset</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD5</td><td align="left" valign="top" rowspan="1" colspan="1">BL1a</td><td align="left" valign="top" rowspan="1" colspan="1">PE&#8208;Cy5.5</td><td align="left" valign="top" rowspan="1" colspan="1">T&#8208;cell lineage, B&#8208;cell subset</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD7</td><td align="left" valign="top" rowspan="1" colspan="1">8H8.1</td><td align="left" valign="top" rowspan="1" colspan="1">FITC</td><td align="left" valign="top" rowspan="1" colspan="1">T&#8208;cell lineage, T&#8208;cell activation, NK&#8208;cell subsets</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD16</td><td align="left" valign="top" rowspan="1" colspan="1">B73.1</td><td align="left" valign="top" rowspan="1" colspan="1">PE</td><td align="left" valign="top" rowspan="1" colspan="1">T&#8208;cell subsets, NK cells, monocyte differentiation, eosinophil exclusion, myeloid lineage</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD56</td><td align="left" valign="top" rowspan="1" colspan="1">NCAM16.2</td><td align="left" valign="top" rowspan="1" colspan="1">PE</td><td align="left" valign="top" rowspan="1" colspan="1">NK cells, plasma cell subset</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD19</td><td align="left" valign="top" rowspan="1" colspan="1">J3.119</td><td align="left" valign="top" rowspan="1" colspan="1">ECD</td><td align="left" valign="top" rowspan="1" colspan="1">B&#8208;cell lineage</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD20</td><td align="left" valign="top" rowspan="1" colspan="1">B9E9</td><td align="left" valign="top" rowspan="1" colspan="1">PacB</td><td align="left" valign="top" rowspan="1" colspan="1">Mature B cells</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Igkappa</td><td align="left" valign="top" rowspan="1" colspan="1">Rb&#8208;anti&#8208;Hu<xref rid="cytoa24511-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">APC</td><td align="left" valign="top" rowspan="1" colspan="1">B&#8208;cell subset, B&#8208;cell lineage clonality</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Iglambda</td><td align="left" valign="top" rowspan="1" colspan="1">Rb&#8208;anti&#8208;Hu<xref rid="cytoa24511-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">PE</td><td align="left" valign="top" rowspan="1" colspan="1">B&#8208;cell subset, B&#8208;cell lineage clonality</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD138</td><td align="left" valign="top" rowspan="1" colspan="1">B&#8208;B4</td><td align="left" valign="top" rowspan="1" colspan="1">FITC</td><td align="left" valign="top" rowspan="1" colspan="1">Plasma cells</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD14</td><td align="left" valign="top" rowspan="1" colspan="1">RM052</td><td align="left" valign="top" rowspan="1" colspan="1">ECD</td><td align="left" valign="top" rowspan="1" colspan="1">Mature monocytes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD36</td><td align="left" valign="top" rowspan="1" colspan="1">FA6.152</td><td align="left" valign="top" rowspan="1" colspan="1">APC&#8208;AF700</td><td align="left" valign="top" rowspan="1" colspan="1">Monocyte lineage, erythroid lineage, megakaryocytes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD33</td><td align="left" valign="top" rowspan="1" colspan="1">D3HL60.251</td><td align="left" valign="top" rowspan="1" colspan="1">PE&#8208;Cy5.5</td><td align="left" valign="top" rowspan="1" colspan="1">Monocyte lineage, myeloid lineage</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD15</td><td align="left" valign="top" rowspan="1" colspan="1">80H5</td><td align="left" valign="top" rowspan="1" colspan="1">PacB</td><td align="left" valign="top" rowspan="1" colspan="1">Myeloid lineage</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD34</td><td align="left" valign="top" rowspan="1" colspan="1">581</td><td align="left" valign="top" rowspan="1" colspan="1">PE&#8208;Cy7</td><td align="left" valign="top" rowspan="1" colspan="1">Progenitor cells</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD117</td><td align="left" valign="top" rowspan="1" colspan="1">104D2D1</td><td align="left" valign="top" rowspan="1" colspan="1">APC</td><td align="left" valign="top" rowspan="1" colspan="1">Myeloid precursors</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD10</td><td align="left" valign="top" rowspan="1" colspan="1">ALB1</td><td align="left" valign="top" rowspan="1" colspan="1">APC&#8208;AF700</td><td align="left" valign="top" rowspan="1" colspan="1">B&#8208;cell precursors, mature neutrophils</td></tr></tbody></table><table-wrap-foot id="cytoa24511-ntgp-0002"><fn id="cytoa24511-note-0001"><p>Abbreviations: AF, AlexaFluor; APC, allophycocyanin; Cy, cyanin; ECD, energy&#8208;coupled dye (PE coupled to Texas Red); FITC, fluorescein isothiocyanate; KO, Krome Orange; PacB, Pacific Blue; PE, R&#8208;phycoerythrin; WBC, white blood cells.</p></fn><fn id="cytoa24511-note-0002"><label>
<sup>a</sup>
</label><p>Polyclonal rabbit&#8208;anti&#8208;human antibody.</p></fn></table-wrap-foot></table-wrap><p>Testing of the panel was performed on a Navios (10&#8208;color/3&#8208;laser instrument; Beckman Coulter; see <xref rid="cytoa24511-supitem-0002" ref-type="supplementary-material">Table S1</xref>). KALUZA&#8482; analysis software was used to establish a suitable analysis protocol (Table&#160;<xref rid="cytoa24511-tbl-0003" ref-type="table">3</xref>) with Boolean gating to separate expression patterns of the various stacked mAbs in the different channels. Thereby, we could identify the main subpopulations of all hematopoietic lineages and malignant aberrancies in this one&#8208;tube panel (Figure&#160;<xref rid="cytoa24511-fig-0001" ref-type="fig">1</xref>).</p><table-wrap position="float" id="cytoa24511-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Gating strategy of the 21&#8208;mAb 10&#8208;color panel to identify and characterize the relevant cell populations adequately</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th style="border-right:solid 1px #000000" align="left" valign="bottom" rowspan="1" colspan="1">Population of interest</th><th style="border-right:solid 1px #000000" align="left" valign="bottom" rowspan="1" colspan="1">mAbs to select populations</th><th style="border-right:solid 1px #000000" align="left" valign="bottom" rowspan="1" colspan="1">Relevant Abs in respective stacked combination</th><th style="border-right:solid 1px #000000" align="left" valign="bottom" rowspan="1" colspan="1">Identification purpose</th><th style="border-right:solid 1px #000000" align="left" valign="bottom" rowspan="1" colspan="1">Used Abs to detect subset in selected population</th></tr></thead><tbody valign="top"><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<bold>Lymphocytes</bold>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">CD45</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">CD45 KO</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<bold>Monocytes</bold>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">CD45</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">CD45 KO</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<bold>Myeloid cells</bold>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">CD45</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">CD45 KO</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<bold>Precursors</bold>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">CD45</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">CD45 KO</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<bold>Plasma cells</bold>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<bold>CD138</bold>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">CD7 <bold>CD138</bold>
<styled-content style="color:#1C1D1E">FITC</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#FF0000">T cells</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#FF0000">CD3</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#FF0000">CD3</styled-content> APC&#8208;AF750</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">T&#8208;cell activation</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#FF0000">CD2 CD5 CD7</styled-content>
</td></tr><tr><td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Within lymphocytes and precursors</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#FF0000">CD7</styled-content>
<styled-content style="color:#1C1D1E">CD138 FITC</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">Helper T cell</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#FF0000">CD4+ CD8&#8208;</styled-content>
</td></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#FF0000">CD5</styled-content>
<styled-content style="color:#1C1D1E">CD33 PE&#8208;Cy5.5</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">Cytotoxic T cell</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#FF0000">CD4&#8208; CD8+</styled-content>
</td></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#FF0000">CD4</styled-content>
<styled-content style="color:#1C1D1E">CD34 PE&#8208;Cy7</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">T&#8208;cell subset</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#FF0000">CD4+CD8+</styled-content>
</td></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#FF0000">CD2</styled-content>
<styled-content style="color:#1C1D1E">CD10 CD36 APC&#8208;AF700</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">T&#8208;cell subset</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#FF0000">CD4&#8208;CD8&#8208;</styled-content>
</td></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#FF0000">CD8</styled-content>
<styled-content style="color:#1C1D1E">CD15 CD20 PacB</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#0000FF">B cells</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#0000FF">CD19</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">CD16 CD56 <styled-content style="color:#0000FF">Iglambda</styled-content> PE</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">Clonality in B cells</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#0000FF">Igkappa/Iglambda</styled-content>
</td></tr><tr><td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Within lymphocytes and precursors</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#1C1D1E">CD117</styled-content>
<styled-content style="color:#0000FF">Igkappa</styled-content>
<styled-content style="color:#1C1D1E">APC</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">B&#8208;cell precursor</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#0000FF">CD10+ CD20&#8722; CD20dim</styled-content>
</td></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#1C1D1E">CD2</styled-content>
<styled-content style="color:#0000FF">CD10</styled-content>
<styled-content style="color:#1C1D1E">CD36 APC&#8208;AF700</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">Mature B cell</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#0000FF">CD10&#8722; CD20+</styled-content>
</td></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#1C1D1E">CD8 CD15</styled-content>
<styled-content style="color:#0000FF">CD20</styled-content>
<styled-content style="color:#1C1D1E">PacB</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#69D804">NK cells</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#69D804">CD3&#8722; CD16/CD56+</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#69D804">CD3</styled-content> APC&#8208;AF750</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Within lymphocytes</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#69D804">CD16 CD56</styled-content> Iglambda PE</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#308205">NK&#8208;T cells</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#308205">CD3+ CD16/CD56+</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#69D804">
<bold>CD3</bold> APC&#8208;AF750</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Within lymphocytes</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#308205">CD16 CD56</styled-content> Iglambda PE</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#8EA9DB">Precursors</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#8EA9DB">CD34 CD117</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#1C1D1E">CD14</styled-content>
<styled-content style="color:#8EA9DB">CD19</styled-content>
<styled-content style="color:#1C1D1E">ECD</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">B&#8208;cell precursor</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#8EA9DB">CD34+ CD117&#8722; CD19+</styled-content>
</td></tr><tr><td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Within CD45dim/SSdim</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">CD5 <styled-content style="color:#8EA9DB">CD33</styled-content> PE&#8208;Cy5.5</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">Myeloid Precursor</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#8EA9DB">CD34+ CD117+ CD33+</styled-content>
</td></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#1C1D1E">CD4</styled-content>
<styled-content style="color:#8EA9DB">CD34</styled-content>
<styled-content style="color:#1C1D1E">PE&#8208;Cy7</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#8EA9DB">CD117</styled-content>
<styled-content style="color:#1C1D1E">Igkappa APC</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#7030A0">Myeloid cells</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#7030A0">CD15+</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">CD5 <styled-content style="color:#7030A0">CD33</styled-content> PE&#8208;Cy5.5</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">Granulocytes</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#7030A0">CD33+ CD15+</styled-content>
</td></tr><tr><td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Within CD45dim/SS+</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#1C1D1E">CD8</styled-content>
<styled-content style="color:#7030A0">CD15</styled-content>
<styled-content style="color:#1C1D1E">CD20 PacB</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#EEB500">Monocytes</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#EEB500">CD14+</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#EEB500">CD14</styled-content>
<styled-content style="color:#1C1D1E">CD19 ECD</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">Monocytes</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#EEB500">CD33++ CD36+</styled-content>
</td></tr><tr><td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Within CD45+/SSdim</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">CD5 <styled-content style="color:#EEB500">CD33</styled-content> PE&#8208;Cy5.5</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#1C1D1E">CD2 CD10</styled-content>
<styled-content style="color:#EEB500">CD36</styled-content>
<styled-content style="color:#1C1D1E">APC&#8208;AF700</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<bold>Plasma cells</bold>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<bold>CD138+</bold>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">CD16 CD56 <bold>Iglambda</bold> PE</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">Plasma cells</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<bold>CD138+ CD19+</bold>
</td></tr><tr><td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Within CD138+</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<bold>CD16 CD56</bold> Iglambda PE</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">Clonality</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<bold>Igkappa/Iglambda</bold>
</td></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#1C1D1E">CD14</styled-content>
<bold>CD19</bold>
<styled-content style="color:#1C1D1E">ECD</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">Abarrant markers</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<bold>CD56+ CD117+</bold>
</td></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<bold>CD5</bold> CD33 PE&#8208;Cy5.5</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">Exclusion of non&#8208;plasma cells</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<bold>CD2 CD10 CD5</bold>
</td></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#1C1D1E">CD117</styled-content>
<bold>Igkappa</bold>
<styled-content style="color:#1C1D1E">APC</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#1C1D1E">CD117</styled-content> Igkappa <styled-content style="color:#1C1D1E">APC</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">
<styled-content style="color:#1C1D1E">
<bold>CD2 CD10</bold> CD36 APC&#8208;AF700</styled-content>
</td><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/><td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="cytoa24511-ntgp-0003"><fn id="cytoa24511-note-0003"><p>
<italic toggle="yes">Note</italic>: The gating procedure of the relevant cell populations is shown in Figure&#160;<xref rid="cytoa24511-fig-0001" ref-type="fig">1</xref>. Color&#8208;marked populations and antibodies are corresponding with the colors in Figure&#160;<xref rid="cytoa24511-fig-0001" ref-type="fig">1</xref>.</p></fn></table-wrap-foot></table-wrap><fig position="float" fig-type="FIGURE" id="cytoa24511-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Staining and evaluation protocol of the new 21&#8208;mAb 10&#8208;color panel. By using the established gating procedure, the combination of 21 mAbs in 10 colors provides optimal information about lymphocyte subsets, monocytes, myeloid cells, precursor cells, and aberrant cell populations. A normal bone marrow was used to establish the efficacy of the 21&#8208;mAb panel. A, Monocytes are excluded from gated cells; B, Lymphocytes, monocytes, granulocytes, and plasma cells are excluded from gated cells; C, T cells, B cells, and NK&#8208;T cells are excluded from gated cells</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="CYTO-101-117-g001.jpg"/></fig><p>Designing such a high&#8208;level powerful screening tool relies on the proper balancing of the panel. Furthermore, the use of correct analysis protocols generates more accurate results by creating more co&#8208;expression pattern and to maximize the evaluation possibilities of samples with low cell counts.</p></sec><sec sec-type="COI-statement" id="cytoa24511-sec-0004"><title>CONFLICT OF INTEREST</title><p>All authors confirm that they have no conflicts of interest with the subjects mentioned in the paper. The authors alone are responsible for the content and writing of the paper.</p></sec><sec id="cytoa24511-sec-0005"><title>AUTHOR CONTRIBUTIONS</title><p>
<bold>Erik H. L. P. G. Huys:</bold> Conceptualization (equal); data curation (equal); formal analysis (equal); investigation (equal); methodology (equal); resources (equal); software (equal); supervision (equal); validation (equal); visualization (equal); writing&#8212;original draft (equal); writing&#8212;review and editing (equal). <bold>Willemijn Hobo:</bold> Writing&#8212;review and editing (equal). <bold>Frank W. M. B. Preijers:</bold> Conceptualization (lead); data curation (equal); funding acquisition (lead); investigation (equal); methodology (equal); project administration (equal); resources (equal); software (equal); supervision (lead); validation (equal); visualization (equal); writing&#8212;original draft (equal); writing&#8212;review and editing (lead).</p></sec><sec id="cytoa24511-sec-0006"><label>3</label><sec id="cytoa24511-sec-0007"><title>PEER REVIEW</title><p>The peer review history for this article is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://publons.com/publon/10.1002/cyto.a.24511" ext-link-type="uri">https://publons.com/publon/10.1002/cyto.a.24511</ext-link>.</p></sec></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="cytoa24511-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>MIFlowCyt</bold>: MIFlowCyt&#8208;Compliant Items.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-101-117-s001.doc" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24511-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Appendix</bold> S1: Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-101-117-s003.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24511-supitem-0003" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>FIGURE S1</bold> A and B Normal BM was spiked with BM of an AML patient having a patient&#8208;specific leukemia&#8208;associated immunophenotype (LAIP) to obtain 4.5% AML cells in the ultimately sample. Subsequently 10<sup>5</sup> (Online Figure 1A.) and 10<sup>3</sup> (Online Figure 1B.) WBC of this mixed sample were flow cytometric analyzed. In the CD45/SS plot the lymphocytes, monocytes and granulocytes and the location of the AML cells to detect the LAIP (gate CD45&#8201;+&#8201;&#8208;) were gated. Each gate is separately further analyzed using plots with the relevant mAb combinations.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-101-117-s004.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24511-supitem-0004" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>FIGURE S2</bold> Representative analysis of a BM sample with the new 21&#8208;mAbs 10&#8208;color panel with suspicion of a lympho&#8208;proliferative process. The lymphoid population (bright CD45 expression) was gated in the CD45/SS plot and lymphoid subpopulations were further defined as T cells (CD3+), NK cells (CD3&#8208;/CD56+), NK&#8208;T cells (CD3+/CD56+) and B cells (CD19+). Within the T cells the CD4/CD8 ratio was normal. The B cells expressed a normal Igkappa / Iglambda ratio and displayed a normal maturation pattern (CD20/CD10). No plasma cell (CD138+) aberrancies were found. No aberrant immature cells were detected in the CD45/SS plot and CD34/CD117 plot.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-101-117-s008.jpeg" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24511-supitem-0005" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>FIGURE S3</bold> Representative analysis of a BM sample with the new 21&#8208;mAbs 10&#8208;color panel with suspicion of acute myeloid leukemia (AML). The lymphoid population (bright CD45 expression) was identified within the CD45/SS plot. Lymphoid subpopulations were further classified as T cells (CD3+), NK cells (CD3&#8208;/CD56+), NK&#8208;T cells (CD3+/CD56+) and B cells (CD19). Within the T&#8208;cells the CD4/CD8 ratio was normal. The B cells expressed a normal Igkappa/Iglambda ratio, though only mature B cell (CD20) were present. No aberrant Plasma cells (CD138+) were found. A large population aberrant immature cells was seen in the CD45/SS plot and CD34/CD117 plots. These aberrant cells also expressed CD33&#8201;+&#8201;.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-101-117-s006.jpeg" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24511-supitem-0006" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>FIGURE S4</bold> Representative analysis of a PB sample with the new 21&#8208;mAbs 10&#8208;color panel with suspicion of evidence of acute lymphoblastic leukemia (ALL). The lymphoid population (bright CD45 expression) was identified within the CD45/SS plot. Lymphoid subpopulations were further classified as T cells (CD3+), NK cells (CD3&#8208;/CD56+), NK&#8208;T cells (CD3+/CD56+) and B cells (CD19). Within the T cells the CD4/CD8 ratio was normal. The B cells expressed a normal Igkappa/ Iglambda ratio and only mature B cells (CD20) were present. No aberrant plasma cells (CD138+) were found. A population of immature cells (CD45+/&#8722; SS and CD34&#8208; CD117+/&#8722; plots) was seen expressing CD19+ CD10+ and CD20+/&#8722;.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-101-117-s005.jpeg" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24511-supitem-0007" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>FIGURE S5</bold> Representative analysis of a BM sample with the new 21&#8208;mAbs 10&#8208;color panel with suspicion of evidence of a monoclonal B cell neoplasia. The lymphoid population (CD45[+]) was identified within the CD45/SS plot. The lymphoid subpopulations were further identified as T cells (CD3+), NK cells (CD3&#8208;/CD56+), NK&#8208;T cells (CD3+/CD56+) and B cells (CD19+).The CD4/CD8 ratio was normal. In contrast, the B&#8208;cell population was aberrant and displayed a restricted Igkappa, CD10&#8208; and CD20+ expression. Furthermore, a small population of plasma cells (CD138+), CD19+ was identified expressing CD117 and Igkappa. Aberrant immature cells were not detected in the CD45&#8201;+&#8201;&#8208; gating of CD45/SS plot in combination with the CD34/CD117 plots.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-101-117-s002.jpeg" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24511-supitem-0008" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>FIGURE S6</bold> Representative analysis of a BM sample with the new 21&#8208;mAbs 10&#8208;color panel with suspicion of evidence of a monoclonal B cell neoplasia. The lymphoid population (bright CD45 expression) was identified within the CD45/SS plot. Lymphoid subpopulations were further identified as T cells (CD3+), NK cells (CD3&#8208;/CD56+), NK&#8208;T cells (CD3+/CD56+) and B cells (CD19+). Within the T cells the CD4/CD8 ratio was normal. The B cells expressed almost only Igkappa and CD20. CD19&#8201;+&#8201;CD5+ B&#8208;lineage cells could not be detected. Only normal plasma cells (CD138+) and immature cells were present in the CD45+/&#8722; SS plot and CD34/CD117 plot.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-101-117-s007.jpeg" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="cytoa24511-sec-0003"><title>ACKNOWLEDGMENT</title><p>The authors thank Dr. Michael Kapinsky, Beckman Coulter, Inc., for support in the panel design.</p></ack><ref-list id="cytoa24511-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="cytoa24511-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cytoa24511-cit-0001"><string-name name-style="western"><surname>Mahnke</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Roederer</surname><given-names>M</given-names></string-name>. <article-title>OMIP&#8208;001: quality and phenotype of ag&#8208;responsive human T&#8208;cells</article-title>. <source>Cytometry A</source>. <year>2010</year>;<volume>77</volume>:<fpage>819</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">20722005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cyto.a.20944</pub-id></mixed-citation></ref><ref id="cytoa24511-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cytoa24511-cit-0002"><string-name name-style="western"><surname>Preijers</surname><given-names>FW</given-names></string-name>, <string-name name-style="western"><surname>Huys</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mosaver</surname><given-names>B</given-names></string-name>. <article-title>A new 10&#8208;color monoclonal antibody panel for polychromatic immunophenotyping of small hematopoietic cell samples</article-title>. <source>Cytometry A</source>. <year>2012</year>;<volume>81</volume>:<fpage>453</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">22532446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cyto.a.22056</pub-id></mixed-citation></ref><ref id="cytoa24511-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cytoa24511-cit-0003"><string-name name-style="western"><surname>Bazinet</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rys</surname><given-names>RN</given-names></string-name>, <string-name name-style="western"><surname>Barry</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Greenwood</surname><given-names>CMT</given-names></string-name>, <string-name name-style="western"><surname>Young</surname><given-names>YK</given-names></string-name>, <string-name name-style="western"><surname>Mendoza</surname><given-names>A</given-names></string-name>, et al. <article-title>A 10&#8208;color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia</article-title>. <source>Leuk Lymphoma</source>. <year>2021</year>;<volume>21</volume>:<fpage>1</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10428194.2021.1919658</pub-id><pub-id pub-id-type="pmid">34020575</pub-id></mixed-citation></ref><ref id="cytoa24511-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cytoa24511-cit-0004"><string-name name-style="western"><surname>Petersen</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Bill</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rosenberg</surname><given-names>CA</given-names></string-name>. <article-title>OMIP 072: a 15&#8208;color panel for immunophenotypic identification, quantification, and characterization of leukemic stem cells in children with acute myeloid leukemia</article-title>. <source>Cytometry A</source>. <year>2021</year>;<volume>99</volume>:<fpage>382</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">33369057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cyto.a.24284</pub-id></mixed-citation></ref><ref id="cytoa24511-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cytoa24511-cit-0005"><string-name name-style="western"><surname>Keeney</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hedley</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Chin&#8208;Yee</surname><given-names>IH</given-names></string-name>. <article-title>Flow cytometry&#8208;recognizing unusual populations in leukemia and lymphoma diagnosis</article-title>. <source>Int J Lab Hematol</source>. <year>2017</year>;<volume>39</volume>(<issue>1</issue>):<fpage>86</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="pmid">28447408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ijlh.12666</pub-id></mixed-citation></ref><ref id="cytoa24511-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cytoa24511-cit-0006"><string-name name-style="western"><surname>Van Dongen</surname><given-names>JJM</given-names></string-name>, <string-name name-style="western"><surname>Lhermitte</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>B&#246;ttcher</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Almeida</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>van der Velden</surname><given-names>VHJ</given-names></string-name>, <string-name name-style="western"><surname>Flores&#8208;Montero</surname><given-names>J</given-names></string-name>, et al. <article-title>EuroFlow antibody panels for standardized n&#8208;dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes</article-title>. <source>Leukemia</source>. <year>2012</year>;<volume>26</volume>:<fpage>1908</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">22552007</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/leu.2012.120</pub-id><pub-id pub-id-type="pmcid">PMC3437410</pub-id></mixed-citation></ref><ref id="cytoa24511-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cytoa24511-cit-0007"><string-name name-style="western"><surname>Hobo</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Broen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>van der Velden</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Greupink&#8208;Draaisma</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Adisty</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Wouters</surname><given-names>Y</given-names></string-name>, et al. <article-title>Association of disparities in known minor histocompatibility antigens with relapse&#8208;free survival and graft&#8208;versus&#8208;host&#8208;disease after allogeneic stem cell transplantation</article-title>. <source>Biol Blood Marrow Transplant</source>. <year>2013</year>;<volume>19</volume>:<fpage>274</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">23022467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbmt.2012.09.008</pub-id><pub-id pub-id-type="pmcid">PMC3553241</pub-id></mixed-citation></ref><ref id="cytoa24511-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cytoa24511-cit-0008"><string-name name-style="western"><surname>Zeijlemaker</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Kelder</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Oussoren&#8208;Brockhoff</surname><given-names>YJ</given-names></string-name>, <string-name name-style="western"><surname>Scholten</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Snel</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Veldhuizen</surname><given-names>D</given-names></string-name>, et al. <article-title>A simple one&#8208;tube assay for immuno&#8208;phenotypical quantification of leukemic stem cells in acute myeloid leukemia</article-title>. <source>Leukemia</source>. <year>2016</year>;<volume>30</volume>:<fpage>439</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">26437777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/leu.2015.252</pub-id></mixed-citation></ref><ref id="cytoa24511-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cytoa24511-cit-0009"><string-name name-style="western"><surname>Rajab</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Axler</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Leung</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wozniak</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Porwit</surname><given-names>A</given-names></string-name>. <article-title>Ten&#8208;color 15&#8208;antibody flow cytometry panel for immunophenotyping of lymphocyte population</article-title>. <source>Int J Lab Hematol</source>. <year>2017</year>;<volume>39</volume>(<issue>1</issue>):<fpage>76</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ijlh.12678</pub-id><pub-id pub-id-type="pmid">28447425</pub-id></mixed-citation></ref><ref id="cytoa24511-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cytoa24511-cit-0010"><string-name name-style="western"><surname>Hedley</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Keeney</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Popma</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chin&#8208;Yee</surname><given-names>I</given-names></string-name>. <article-title>Novel lymphocyte screening tube using dried monoclonal antibody reagents</article-title>. <source>Cytometry B</source>. <year>2015</year>;<volume>88</volume>:<fpage>361</fpage>&#8211;<lpage>70</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cyto.b.21251</pub-id><pub-id pub-id-type="pmid">25944189</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>